Overview
ProcDNA focuses on commercial analytics and technology consulting for life sciences and biopharma. It helps clients turn data into actionable insights through analytics, technology, and data science services, including specialized offerings like Auxo HCP 360 for data management, marketing, and customer relationship optimization. The company delivers tailored solutions in areas such as commercial planning, market assessment, and patient journey quantification, enabling precise business decisions and growth. What sets ProcDNA apart is its deep expertise in market access analytics, sales strategy, and campaign ROI, backed by a leadership team with over a century of combined experience, a track record with 25 clients across 40 disease indications, and a presence in five office locations. The overarching goal is to drive growth for biopharma clients by turning complex data into clear, strategic actions.
Work here?Claim your company
Simplify's Take
What believers are saying
- August 2026 Bengaluru expansion signals demand for more delivery capacity and client work.
- March 16, 2026 Reuters Pharma presence supports lead generation across commercial and medical functions.
- June 2026 Business Circle recognition strengthens recruiting and enterprise credibility with biopharma clients.
What critics are saying
- ProcDNA disclosed no funding, creating dependence on services revenue and sales execution.
- Glassdoor's 2025 reviews showed 58% recommendation and 2.4 work-life balance, pressuring retention.
- A Veeva or conference-intelligence imitation from Accenture, IQVIA, or ZS erodes differentiation by 2027.
What makes ProcDNA unique
- ProcDNA's 2026 Veeva Services Partner status deepens execution credibility with life sciences buyers.
- Its January 2026 Conference Intelligence package spans oncology, neurology, dermatology, cardiology, and endocrinology.
- ProcDNA reached 400-plus professionals across eight locations by January 2026.
Help us improve and share your feedback! Did you find this helpful?